Clinical Research
Enhance Your Clinical Studies with RetInSight's AI-Powered Software Solutions
cAIre – center for AI reading excellence
At RetInSight, we specialize in transforming clinical trials through advanced AI-driven software that automates the diagnosis and monitoring of retinal disease biomarkers via Optical Coherence Tomography (OCT).
RetInSight cAIre – "center for AI reading excellence" – supports biotechnology and pharmaceutical companies in their clinical development for retinal diseases, e.g. geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Our solutions provide unparalleled precision, efficiency, and insights, making clinical trials more robust, faster, and cost-effective.
Why choose RetInSight for your clinical trial?
Integrating AI into your clinical trials offers significant advantages, including fully automated, quantitative, and reproducible readouts that surpass human expert assessments. By leveraging AI to gain new insights from existing real-world data, you can reduce overall study costs, accelerate study timelines, and ultimately increase your trial’s success rate.
Embrace AI-driven solutions to streamline your research and achieve impactful results.
From manual grading to fully-automated AI analysis of OCT images
With cAIre, you can overcome the limitations of traditional manual reading centers.
Unlike manual grading, which is confined to limited fields, thickness measurements, and prone to inter-reader variability, cAIre utilizes AI-based segmentation that is guided by human ground truth, ensuring precise and consistent results.
AI solutions for every stage of your study
AI tools for all stages of a clinical study, prospective and retrospective
In prospective clinical studies
In your prospective clinical studies, the RetInSight AI tools are available for
- pre-screening of patients already filtering the optimal patient cohort based on historical data sets,
- real-time screening at sites streamlining the patient selection process and saving valuable time and money,
- monitoring your patients throughout the study allowing an increased doctor-patient communication,
- and additional AI analysis at the end of the study to optimally leverage and substantiate your data set, favourably impacting your differentiation.
AI tools for all stages of a clinical study, prospective and retrospective
For retrospective analysis
In case you have your (interim or final) OCT data set in hands and think about the next step, RetInSight offers to generate insights via retrospective analysis for data substantiation, thus, potentially increasing the success rate of your subsequent clinical studies.
Elevate your clinical trial with AI-based reading excellence
At RetInSight, we are specialized in AI-based reading services. However, we also act as a central reading center by collaborating with world-class manual reading centers providing traditional manual grading of e.g. fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF) images.
FAQs
What types of AI‑based image analysis does RetInSight provide for clinical research?
RetInSight provides automated AI‑based segmentation and quantification of OCT imaging for use in sponsored clinical trials.
The research algorithms extract objective, layer‑specific structural information from OCT scans, supporting analysis in conditions such as nAMD, DME, RVO, and GA.
These tools process large datasets consistently and can be used to support exploratory imaging endpoints and structural assessments across multi‑site trials.
Which disease areas are supported by RetInSight’s AI tools in clinical studies?
RetInSight’s AI suite supports clinical research in several retinal diseases where OCT imaging is a core component of evaluation, including:
- Neovascular AMD (nAMD)
- Diabetic Macular Edema (DME)
- Retinal Vein Occlusions (RVO)
- Geographic Atrophy (GA)
The algorithms are optimized for the structural biomarkers relevant to each of these disease areas, enabling consistent analysis across large numbers of scans.
How does AI improve data consistency and quality across multi‑site clinical trials?
Clinical trials often include multiple sites, imaging devices, and graders, which can introduce variability into OCT‑based assessments.
RetInSight’s AI tools help reduce this variability by:
- applying consistent segmentation rules to every scan
- generating reproducible quantitative outputs independent of grader or site
- enabling image analysis across global study locations
- supporting large‑scale data processing with uniform biomarker definitions
This helps sponsors, CROs, and reading centers improve dataset reliability and streamline analysis workflows.
Who uses RetInSight’s AI solutions in clinical research?
Customers typically include:
- Pharmaceutical companies running Phase I–IV or post‑marketing studies
- Biotech companies developing retinal therapies
- Contract Research Organizations (CROs)
- Commercial reading centers
- Large clinical trial sites participating in sponsored studies
What is cAIre and how does it support clinical research?
The cAIre (Center for AI-Powered Reading Excellence) division offers a full service package for AI‑based OCT image analysis, including:
- validated biomarker algorithms
- standardized workflows across global study sites
- quality control by experienced graders
- scientific and medical oversight
- support for regulatory documentation and submissions within the scope of the provided service
It is designed for sponsors, CROs, and reading centers running large or multicenter trials.
Which OCT devices are supported in clinical research?
RetInSight currently supports:
- Heidelberg Spectralis OCT (for all research solutions)
- Topcon Triton OCT (for fluid analysis in research)
- Topcon Maestro OCT
- Zeiss Cirrus OCT
Support for additional devices can be added if required by a study sponsor and after completing device‑specific validation.
Can RetInSight support both retrospective and prospective studies?
Yes.
- Retrospective datasets: processed via batch analysis
- Prospective studies: processed in real time through cAIre direct
This flexibility supports both early‑stage and late‑stage clinical development programs.
What is cAIre direct and how is it used in prospective clinical studies?
cAIre direct is a secure, cloud‑based platform that allows sponsored study sites to:
- upload OCT scans
- trigger AI analysis
- access biomarker results
- manage cohorts and datasets
- download outputs for data integration
It enables AI‑powered image analysis without requiring PACS integration, making it ideal for multicenter industry trials.
How is data privacy handled in clinical research?
All study data is:
- pseudonymized
- encrypted at rest and in transit
- processed under GDPR, ISO 27001, and MDR requirements
cAIre direct includes full access control and audit logs for sponsor governance.
Interested in learning how we can support YOUR study? Contact us, because we cAIre about your clinical study!